ALVOTECH
25.3.2021 15:52:05 CET | Business Wire | Press release
Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab). Alvotech will vigorously defend against these allegations.
Notably, AbbVie waited over three years from the purported date of the alleged wrongdoing to file its case, doing so after the ex-AbbVie employee had already left Alvotech and without naming the ex-AbbVie employee as a defendant.
This lack of urgency causes Alvotech to question the motivation behind the case. Indeed, Alvotech believes that the case may be part of a larger AbbVie strategy to delay an emerging competitor from providing patients with a lower-cost alternative to AbbVie’s HUMIRA® high-concentration product.
Alvotech will continue its efforts to increase accessibility to high quality and affordable medicines.
About Alvotech:
Alvotech is a multinational biopharmaceutical company focused on the development and manufacture of high quality biosimilars for global markets. We are specialists in biotechnology, seeking to be a global leader in the biosimilar space by delivering high quality, cost-competitive products and services to our partners and to patients worldwide. Our fully integrated approach, with high-quality in-house competencies throughout the value chain, enables the accelerated development of biosimilar products. Alvotech’s shareholder base includes, among others, Aztiq Pharma, led by founder and Chairman Mr. Robert Wessman, Cipla Gulf FZ from Australia and New Zeland, Shinhan from Korea, Baxter Healthcare SA, YAS Holdings, ATHOS (Strüngmann Family Office), CVC Capital Partners and Temasek from Singapore.
Alvotech‘s initial pipeline contains several monoclonal-antibody and fusion-protein biosimilar candidates aimed at treating autoimmunity, oncology and inflammatory conditions to improve quality of life for patients around the world. For more information, please visit our website, www.alvotech.com or follow us on LinkedIn , Twitter and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005659/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days* Without Regulatory Risks13.5.2026 13:05:00 CEST | Press release
InStat™ delivers submission-ready tables, lists and figures (TLF) on validated statistical engines, with Clene Nanomedicine as its first customer Veristat™, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced the launch of InStat™ by Veristat. InStat is the clinical research industry’s first zero-code, fully automated biostatistics solution, reducing manual effort to speed time to approval with every output backed by validated statistical engines and expert biostatistician review. It delivers submission-ready tables, listings, and figures (TLF) in five days or less*, rather than the four to six weeks sponsors typically wait after database lock, while maintaining the highest quality data. Veristat will begin using InStat to deliver biostatistics services in June. Clene Nanomedicine is the first clinical trial sponsor whose work was delivered using InStat, with NfL biomarker analyses supporting their planned 2026 New Drug Application (
Carta Launches Carta Law with Acquisition of Avantia13.5.2026 13:01:00 CEST | Press release
Acquisition marks launch of the largest AI-native law firm for private capital, combining institutional expertise with agent-orchestrated workflows to accelerate fund operations Carta, the agentic enterprise resource planning (ERP) platform for private capital, today announced it has acquired Avantia, a leading AI-powered legal and compliance law firm for asset managers. The acquisition launches Carta Law—the largest AI-native, integrated legal and compliance solution for private markets—unifying legal and compliance workflows with fund operations on a single platform. Private capital firms have long operated with fragmented infrastructure, with fund administration, compliance, and legal services spread across separate vendors. Deal teams wait days for NDAs. Limited partner onboarding to new funds is delayed by KYC backlogs. General counsels lose visibility into legal spend or institutional precedent. As deal velocity increases and regulatory complexity grows, this fragmentation become
Amazfit Unveils the Cheetah 2 Ultra: The Performance Trail Running Watch Built to Master the Toughest Mountain Trails13.5.2026 13:00:00 CEST | Press release
Built for ultra distances and mountain racing, the Cheetah 2 Ultra combines long battery life, precision navigation, and advanced training insights to carry more distance and control more load Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Cheetah 2 Ultra. Building on the momentum of the recently launched Cheetah 2 Pro—designed for road marathoners—the Ultra is a specialized instrument for trail runners who measure success in elevation, unpredictable terrain, and hours spent on the move. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513230718/en/ Built for ultra distances and mountain racing, the Cheetah 2 Ultra combines long battery life, precision navigation, and advanced training insights to carry more distance and control more load. Amazfit’s Cheetah 2 Ultra is built for runners who prepare for ultra distances and mountain races, boasting 33-hour trail running optimized GPS b
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights13.5.2026 12:30:00 CEST | Press release
FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 dataCNPV awarded for COMP360 in TRD, further accelerating momentum26-week (Part B) data from COMP006, expected in early Q3 2026Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of yearSuccessful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights. “With regulatory acceleration unfolding, we are working diligently towards our goal of completing the filing of a robust clinical package by Q4 and securing COMP360 approval,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “COMP360 repr
Uptime Announces Annual Outage Analysis Report 202613.5.2026 12:02:00 CEST | Press release
8th Annual Report analyzes data on IT and data center outages including causes, frequency, costs, and consequences Uptime Institute today announced the release of its 8th Annual Outage trends report, an ongoing series from Uptime Institute Intelligence analyzing IT service resiliency. Outage prevention continues to be a central focus for data center operators as demand growth, AI-driven workloads and power constraints reshape risk profiles. As design and operations improve, operators must still navigate greater system complexity, grid instability, deeper interdependencies and evolving external threats. The 8th Annual Outage Analysis 2026 report analyzes recent data on the causes, frequency and consequences of IT and data center outages. For the fifth consecutive year, Uptime Intelligence Research suggests that outage frequency on a per-site basis is declining. However, the pace of improvement has slowed compared to previous years and approximately 1 in 10 note their last outage had ser
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom